J&J: Covid-19 vaccine enters late-stage testing
(CercleFinance.com) - Johnson & Johnson said that it is advancing its experimental vaccine candidate for the prevention of Covid-19 in a final-stage clinical trial.
The Phase 3 trial on the investigational vaccine, which is being developed by J&J's biopharma unit Janssen, is set to enroll up to 60,000 participants worldwide, the drugmaker said.
In addition to the single-dose regimen study, Janssen has now begun a complementary Phase 3 trial that will study the safety and efficacy of a two-dose regimen, in up to 30,000 participants, Johnson & Johnson said.
Janssen's Covid-19 vaccine candidate leverages a technology platform, which has been used to develop and manufacture an EU-approved Ebola vaccine and built its Zika and HIV investigational vaccine candidates.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The Phase 3 trial on the investigational vaccine, which is being developed by J&J's biopharma unit Janssen, is set to enroll up to 60,000 participants worldwide, the drugmaker said.
In addition to the single-dose regimen study, Janssen has now begun a complementary Phase 3 trial that will study the safety and efficacy of a two-dose regimen, in up to 30,000 participants, Johnson & Johnson said.
Janssen's Covid-19 vaccine candidate leverages a technology platform, which has been used to develop and manufacture an EU-approved Ebola vaccine and built its Zika and HIV investigational vaccine candidates.
Copyright (c) 2020 CercleFinance.com. All rights reserved.